A specialty pharmaceutical company focused on using innovative and patent-protected topical drug delivery platforms, Quinnova Pharmaceuticals, Inc., appointed Dr. Chet Evans, Barry University’s School of Podiatric Medicine Dean, to its scientific advisory board.
“Dr. Evans is held in high esteem by the academic medical and podiatric communities,” said Quinnova President and CEO Jeffrey S. Day. He described Evan’s experience in the field as a strong motivator for choosing him.
Quinnova’s mission is to develop and market easy-to-use dermal prescription drug products that provide treatment solutions to clinicians and patients, alike. Their Proderm Technology, is not only used as the delivery system for a variety of topically applied medications but also as an agent that restores the impaired natural skin barrier associated with inflammatory and infectious skin disorders.